These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21288186)

  • 1. Telomeres as targets for anticancer therapies.
    Folini M; Venturini L; Cimino-Reale G; Zaffaroni N
    Expert Opin Ther Targets; 2011 May; 15(5):579-93. PubMed ID: 21288186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
    Kelland L
    Clin Cancer Res; 2007 Sep; 13(17):4960-3. PubMed ID: 17785545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the telosome: therapeutic implications.
    Folini M; Gandellini P; Zaffaroni N
    Biochim Biophys Acta; 2009 Apr; 1792(4):309-16. PubMed ID: 19419699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The levels of telomere-binding proteins in human tumours and therapeutic implications.
    Cookson JC; Laughton CA
    Eur J Cancer; 2009 Mar; 45(4):536-50. PubMed ID: 19114299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.
    Jafri MA; Ansari SA; Alqahtani MH; Shay JW
    Genome Med; 2016 Jun; 8(1):69. PubMed ID: 27323951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting telomeres and telomerase.
    De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
    Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
    Raymond E; Faivre S; Dieras V; Von Hoff D
    Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomere maintenance as a target for anticancer drug discovery.
    Neidle S; Parkinson G
    Nat Rev Drug Discov; 2002 May; 1(5):383-93. PubMed ID: 12120414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligonucleotides Targeting Telomeres and Telomerase in Cancer.
    Schrank Z; Khan N; Osude C; Singh S; Miller RJ; Merrick C; Mabel A; Kuckovic A; Puri N
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30189661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
    Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
    Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligonucleotides and G-quadruplex stabilizers: targeting telomeres and telomerase in cancer therapy.
    Crees Z; Girard J; Rios Z; Botting GM; Harrington K; Shearrow C; Wojdyla L; Stone AL; Uppada SB; Devito JT; Puri N
    Curr Pharm Des; 2014; 20(41):6422-37. PubMed ID: 24975605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
    Tárkányi I; Aradi J
    Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to senescence induction and telomere shortening by a G-quadruplex ligand inhibitor of telomerase.
    Gomez D; Aouali N; Renaud A; Douarre C; Shin-Ya K; Tazi J; Martinez S; Trentesaux C; Morjani H; Riou JF
    Cancer Res; 2003 Oct; 63(19):6149-53. PubMed ID: 14559794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human telomeric G-quadruplex: the current status of telomeric G-quadruplexes as therapeutic targets in human cancer.
    Neidle S
    FEBS J; 2010 Mar; 277(5):1118-25. PubMed ID: 19951354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in targeting the telomeric G-quadruplex DNA sequence with small molecules as a strategy for anticancer therapies.
    Islam MK; Jackson PJ; Rahman KM; Thurston DE
    Future Med Chem; 2016 Jul; 8(11):1259-90. PubMed ID: 27442231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G-quadruplex stabilizer 3,6-bis(1-methyl-4-vinylpyridinium)carbazole diiodide induces accelerated senescence and inhibits tumorigenic properties in cancer cells.
    Huang FC; Chang CC; Lou PJ; Kuo IC; Chien CW; Chen CT; Shieh FY; Chang TC; Lin JJ
    Mol Cancer Res; 2008 Jun; 6(6):955-64. PubMed ID: 18515756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods of studying telomere damage induced by quadruplex-ligand complexes.
    Rizzo A; Salvati E; Biroccio A
    Methods; 2012 May; 57(1):93-9. PubMed ID: 22410593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase inhibition alters telomere maintenance mechanisms in laryngeal squamous carcinoma cells.
    Chen W; Chen SM; Yu Y; Xiao BK; Huang ZW; Tao ZZ
    J Laryngol Otol; 2010 Jul; 124(7):778-83. PubMed ID: 20403221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of telomere-binding proteins in carcinogenesis].
    Aragona M; Pontoriero A; Panetta S; La Torre I; La Torre F
    Minerva Med; 2000; 91(11-12):299-304. PubMed ID: 11253711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.